{"doi":"10.1016/j.ejmech.2019.111682","title":"Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)","abstract":null,"journal":"European Journal of Medicinal Chemistry","year":2019,"id":639411,"datarank":5.416667137751486,"base_score":5.147494476813453,"endowment":5.147494476813453,"self_citation_contribution":0.7721241715220181,"citation_network_contribution":4.644542966229468,"self_endowment_contribution":0.7721241715220181,"citer_contribution":4.644542966229468,"corpus_percentile":null,"corpus_rank":null,"citation_count":171,"citer_count":166,"citers_with_citation_signal":139,"citers_with_endowment":139,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1402932,"name":"Dandan Guo","orcid":"0000-0002-6829-1356","position":1,"is_corresponding":false},{"id":1129989,"name":"Zhongliang Jiang","orcid":"0000-0001-7461-2200","position":2,"is_corresponding":false},{"id":1661251,"name":"Rongsheng Tong","orcid":null,"position":3,"is_corresponding":false},{"id":1661252,"name":"Peidu Jiang","orcid":null,"position":4,"is_corresponding":false},{"id":1661253,"name":"Lan Bai","orcid":null,"position":5,"is_corresponding":false},{"id":625526,"name":"Lu Chen","orcid":"0000-0003-2906-2507","position":6,"is_corresponding":false},{"id":681365,"name":"Yuxuan Zhu","orcid":"0000-0001-6686-2736","position":7,"is_corresponding":false},{"id":297893,"name":"Chun Guo","orcid":"0000-0002-1540-3166","position":8,"is_corresponding":false},{"id":1661254,"name":"Jianyou Shi","orcid":null,"position":9,"is_corresponding":false},{"id":312856,"name":"Dongke Yu","orcid":null,"position":10,"is_corresponding":false},{"id":1661250,"name":"Zhuyu Xu","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)","abstract":"Targeted drug delivery has improved cancer treatment significantly in recent years, although it is difficult to achieve. Different approaches have been developed to apply targeted drug delivery. Among which, antibody-drug conjugate (ADC) provides a potentially ideal solution to such a challenge. ADC is an innovative drug treatment model with three key components: payload, monoclonal antibody, and linker. The monoclonal antibody targets the antigen-expressing tumor cells and internalizes the payload linked by the linker to the target cells to reduce the side effects of the traditional chemotherapy drugs. The off-target effect has an excellent therapeutic prospect. Among them, ado-trastuzumab emtansine (T-DM1) is a successful example of targeting human epidermal growth factor receptor-2 (HER2). Its antibody (trastuzumab) is derived from Herceptin with annual sales of more than $6 billion. It has excellent targeting and specific anti-tumor activity against HER2. Its linker is not cleavable and releases the Lys-linker-payload to kill the cells. The two ADCs described here use the same antibody as T-DM1, but the cleavable linker and the more toxic payload allow them to have the not only targeting of T-DM1, but also the reduce T-DM1 resistance and improve efficacy in heterogeneous tumors. This paper describes the mechanism of action and the biochemical characteristics of different parts and preclinical and clinical progress of trastuzumab deruxtecan(DS-8201a) and (vic-)trastuzumab duocarmazine (SYD985).","is_dataset_classified":null,"base_score":5.147494476813453,"endowment":5.147494476813453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31563805","pmcid":null,"openalex_id":"https://openalex.org/W2971737201","authors":[],"funders":[{"funder_name":"Chengdu Science and Technology Program","grant_id":"2015-HM01-00463-SF","title":null},{"funder_name":"Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital Foundation","grant_id":"2016QN08","title":null},{"funder_name":"Sichuan Science and Technology Program","grant_id":"2018SZ0169","title":null},{"funder_name":"Health Commission of Sichuan Province","grant_id":"150229","title":null}],"total_grants":4,"fwci":6.3515,"citation_percentile":0.9750578,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2019,"count":1},{"year":2020,"count":14},{"year":2021,"count":20},{"year":2022,"count":36},{"year":2023,"count":30},{"year":2024,"count":36},{"year":2025,"count":21},{"year":2026,"count":12}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0223523419308323?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0223523419308323?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ejmech.2019.111682","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31563805","host_type":"repository"}],"fields_of_study":["HER2/EGFR in Cancer Research","Monoclonal and Polyclonal Antibodies Research","Peptidase Inhibition and Analysis"],"mesh_terms":["Trastuzumab","Ado-Trastuzumab Emtansine","Antineoplastic Agents","Breast Neoplasms","Camptothecin","Carcinoma, Non-Small-Cell Lung","Clinical Trials as Topic","Female","Humans","Lung Neoplasms","Stomach Neoplasms","Erb-b2 Receptor Tyrosine Kinases","Receptor, ErbB-2","Immunoconjugates","Drug Resistance, Neoplasm","Antibodies, Monoclonal, Humanized"],"keywords":["Trastuzumab","Antibody-drug conjugate","Linker","Monoclonal antibody","Trastuzumab emtansine","Conjugate","Chemistry","Cancer research","Pharmacology","Antibody","Cancer","Breast cancer","Medicine","Immunology","Internal medicine","Computer science","Bystander effect","Her2","Ado-trastuzumab Emtansine","Trastuzumab Deruxtecan","(Vic-)trastuzumab Duocarmazine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T00:18:16.335860Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}